三维动态多点离焦对比度双效镜片近视控制效果真实世界研究

注册号:

Registration number:

ChiCTR2600121405 

最近更新日期:

Date of Last Refreshed on:

2026-03-30 16:47:18 

注册时间:

Date of Registration:

2026-03-30 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

三维动态多点离焦对比度双效镜片近视控制效果真实世界研究

Public title:

Real-world research on myopia control effect of three-dimensional dynamic multi-point defocus contrast double-effect lens

注册题目简写:

三维动态多点离焦对比度双效镜片近视控制效果真实世界研究

English Acronym:

Real-world research on myopia control effect of three-dimensional dynamic multi-point defocus contrast double-effect lens

研究课题的正式科学名称:

三维动态多点离焦对比度双效镜片近视控制效果真实世界研究

Scientific title:

Real-world research on myopia control effect of three-dimensional dynamic multi-point defocus contrast double-effect lens

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

郑鹏杰 

研究负责人:

周籽秀 

Applicant:

Zheng Pengjie 

Study leader:

Zhou Zixiu 

申请注册联系人电话:

Applicant telephone:

+86 137 5318 0341

研究负责人电话:

Study leader's
telephone:

+86 180 6880 0989

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zpjlxw@163.com

研究负责人电子邮件:

Study leader's E-mail:

54178593@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国江苏省南京市江宁区吉印大道2007号

研究负责人通讯地址:

中国江苏省南京市江宁区吉印大道2007号

Applicant address:

2007 Jiyin Road, Jiangning District, Nanjing, Jiangsu, China

Study leader's address:

2007 Jiyin Road, Jiangning District, Nanjing, Jiangsu, China

申请注册联系人邮政编码:

Applicant postcode:

211102

研究负责人邮政编码:

Study leader's postcode:

211102

申请人所在单位:

南京同仁医院

Applicant's institution:

Nanjing Tongren Hospital

研究负责人所在单位:

南京同仁医院

Affiliation of the Leader:

Nanjing Tongren Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2025-03-081-K001

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

南京同仁医院伦理委员会

Name of the ethic committee:

Ethics Committee of Nanjing Tongren Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-10-29 00:00:00

伦理委员会联系人:

丁振琴

Contact Name of the ethic committee:

Ding Zhenqin

伦理委员会联系地址:

中国江苏省南京市江宁区吉印大道2007号

Contact Address of the ethic committee:

2007 Jiyin Road, Jiangning District, Nanjing, Jiangsu, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 135 8511 0353

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

南京同仁医院

Primary sponsor:

Nanjing Tongren Hospital

研究实施负责(组长)单位地址:

中国江苏省南京市江宁区吉印大道2007号

Primary sponsor's address:

2007 Jiyin Road, Jiangning District, Nanjing, Jiangsu, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

南京

Country:

China

Province:

Jiangsu

City:

Nanjing

单位(医院):

南京同仁医院

具体地址:

中国江苏省南京市江宁区吉印大道2007号

Institution
hospital:

Nanjing Tongren Hospital

Address:

2007 Jiyin Road, Jiangning District, Nanjing, Jiangsu, China

经费或物资来源:

江苏玺目光学有限公司

Source(s) of funding:

Jiangsu Ximou Optical Co. , Ltd.

研究疾病:

近视  

Target disease:

Myopia

研究疾病代码:

H52.100

Target disease code:

H52.100

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

单臂 

Study design:

Single arm 

研究目的:

通过对三维动态多点离焦对比度双效镜片的观察,期望能够观察到三维动态多点离焦对比度双效镜片对眼轴有效控制以及提升戴镜舒适度,进而减缓近视度数加深的速度。  

Objectives of Study:

Through the observation of the three-dimensional dynamic multi-point defocus contrast double-effect lens, it is expected to observe that the three-dimensional dynamic multi-point defocus contrast double-effect lens can effectively control the eye axis and improve the wearing comfort, and then slow down the deepening speed of myopic degree.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1. 眼部创伤或手术史; 2. 浅前房或眼压>21 mm Hg; 3. 眼科裂隙灯检查临床异常; 4. 罹患眼角膜炎、红眼病、眼周围急性炎症、青光眼等显著的眼部眼病; 5. 显性斜视; 6. 全身性疾病或其他被认为不适合的条件; 7. 在过去3个月内参与过其他临床试验或使用任何近视控制干预; 8. 只有一只眼睛符合纳入标准; 9. 依从性差,不愿意遵守随访; 10. 研究者认为不适合参加本临床试验者;

Exclusion criteria:

1. history of ocular trauma or surgery; 2. shallow anterior chamber or intraocular pressure > 21 mm Hg; 3. clinical abnormalities on slit lamp examination in ophthalmology; 4. suffering from keratitis, red-eye disease, acute inflammation around the eye, glaucoma and other significant eye diseases; 5. dominant strabismus; 6. systemic disease or other conditions considered unsuitable; 7. has participated in other clinical trials or used any myopia control intervention in the past 3 months; 8. only one eye met the inclusion criteria; 9. poor adherence and reluctance to comply with follow-up; 10. those considered unsuitable for participation in this clinical trial by the investigator;

研究实施时间:

Study execute time:

From 2026-04-01 00:00:00 To 2027-04-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-04-01 00:00:00 To 2026-10-01 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

36

Group:

Trial Group

Sample size:

干预措施:

佩戴三维动态多点离焦对比度双效镜片

干预措施代码:

Intervention:

Wearing 3D dynamic multi-point defocus contrast dual-effect lenses

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

南京 

Country:

China

Province:

Jiangsu

City:

Nanjign

单位(医院):

南京同仁医院 

单位级别:

三级 

Institution
hospital:

Nanjing Tongren Hospital

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

眼轴

指标类型:

主要指标

Outcome:

Axial length

Type:

Primary indicator

测量时间点:

筛选期、戴镜后3个月、戴镜后6个月

测量方法:

IOL-Master 500光学相干生物测量仪

Measure time point of outcome:

Screening visit, 3 months after lens wear, 6 months after lens wear

Measure method:

IOL-Master 500 optical coherence biometer

指标中文名:

等效球镜

指标类型:

主要指标

Outcome:

Equivalent spherical refractive error

Type:

Primary indicator

测量时间点:

筛选期、戴镜后3个月、戴镜后6个月

测量方法:

Topcon KR-800电脑验光仪(睫状肌麻痹下)

Measure time point of outcome:

Screening visit, 3 months after lens wear, 6 months after lens wear

Measure method:

Topcon KR-800 autorefractor under cycloplegia

指标中文名:

脉络膜厚度

指标类型:

主要指标

Outcome:

Choroidal thickness

Type:

Primary indicator

测量时间点:

筛选期、戴镜后6个月

测量方法:

Measure time point of outcome:

Screening visit, 6 months after lens wear

Measure method:

指标中文名:

安全性指标(包括:非接触式眼压(IOP)、戴镜远/近视力、眼底检查、不良事件发生情况)

指标类型:

副作用指标

Outcome:

Safety outcomes including non-contact intraocular pressure (IOP), distance and near visual acuity after lens wear, fundus examination, and adverse events

Type:

Adverse events

测量时间点:

筛选期、戴镜后3个月、戴镜后6个月

测量方法:

Measure time point of outcome:

Screening visit, 3 months after lens wear, 6 months after lens wear

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 5 years
最大 Max age 12 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

于研究结果发表之后的6个月内,预计2025年6月-12月内公开,向研究者联系索取

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Within 6 months after the publication of the study results, it is expected to be published between June and December 2025, and the researchers will be contacted for request

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集:病例记录表 数据管理:两名录入员分别录入(独立双录入),各自保存成不同的数据文件,然后把两个数据做比对(双校)。数据文件保存在研究负责人的电脑中。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection:Case record form, CRF Data Management: Two data entry clerks enter separately (independent double entry), save them as different data files, and then compare the two data (double checking). The data file is saved on the computer of the research leader

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-03-30 16:47:18